ATE463246T1 - Formulierung und verfahren zur behandlung von thrombocythämie - Google Patents

Formulierung und verfahren zur behandlung von thrombocythämie

Info

Publication number
ATE463246T1
ATE463246T1 AT04704524T AT04704524T ATE463246T1 AT E463246 T1 ATE463246 T1 AT E463246T1 AT 04704524 T AT04704524 T AT 04704524T AT 04704524 T AT04704524 T AT 04704524T AT E463246 T1 ATE463246 T1 AT E463246T1
Authority
AT
Austria
Prior art keywords
formulation
thrombocythemia
treating
treating thrombocythemia
Prior art date
Application number
AT04704524T
Other languages
English (en)
Inventor
Richard Franklin
Original Assignee
Shire Holdings Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32771969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE463246(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Holdings Ag filed Critical Shire Holdings Ag
Application granted granted Critical
Publication of ATE463246T1 publication Critical patent/ATE463246T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
AT04704524T 2003-01-23 2004-01-23 Formulierung und verfahren zur behandlung von thrombocythämie ATE463246T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44176503P 2003-01-23 2003-01-23
PCT/CA2004/000096 WO2004064841A1 (en) 2003-01-23 2004-01-23 Formulation and methods for the treatment of thrombocythemia

Publications (1)

Publication Number Publication Date
ATE463246T1 true ATE463246T1 (de) 2010-04-15

Family

ID=32771969

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04704524T ATE463246T1 (de) 2003-01-23 2004-01-23 Formulierung und verfahren zur behandlung von thrombocythämie

Country Status (29)

Country Link
US (1) US20040209907A1 (de)
EP (1) EP1589973B2 (de)
JP (1) JP4624978B2 (de)
KR (1) KR20050111317A (de)
CN (1) CN1738623A (de)
AP (1) AP2103A (de)
AT (1) ATE463246T1 (de)
AU (1) AU2004206783B2 (de)
BR (1) BRPI0406634A (de)
CA (1) CA2513708C (de)
CO (1) CO5640120A2 (de)
CY (1) CY1110162T1 (de)
DE (1) DE602004026405D1 (de)
DK (1) DK1589973T4 (de)
EA (2) EA010871B1 (de)
ES (1) ES2344062T5 (de)
HK (1) HK1075844A1 (de)
HR (1) HRP20050633A2 (de)
IL (1) IL169153A (de)
MX (1) MXPA05007287A (de)
NO (1) NO330805B1 (de)
OA (1) OA13018A (de)
PL (1) PL377933A1 (de)
PT (1) PT1589973E (de)
RS (1) RS20050524A (de)
SG (1) SG153661A1 (de)
SI (1) SI1589973T2 (de)
WO (1) WO2004064841A1 (de)
ZA (1) ZA200506056B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10813960B2 (en) * 2000-10-04 2020-10-27 Paul Edward Stamets Integrative fungal solutions for protecting bees and overcoming colony collapse disorder (CCD)
FR2870125B1 (fr) * 2004-05-12 2010-03-26 Dermaconcept Jmc Formulation du type spot-on utile en cosmetologie et en dermatologie
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
CN101534904B (zh) * 2006-09-05 2013-11-06 Abbvie公司 治疗血小板过量的bcl抑制剂
GB0623750D0 (en) * 2006-11-28 2007-01-10 Shire Llc Substituted quinazolines
US7910597B2 (en) 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
GB0623749D0 (en) * 2006-11-28 2007-01-10 Shire Llc Substituted quinazolines
US8304420B2 (en) * 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
CA2924236C (en) 2013-10-07 2020-01-07 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
TWI645866B (zh) 2013-10-07 2019-01-01 美商帝國製藥美國股份有限公司 右美托咪啶經皮輸送裝置及使用其之方法
RU2658463C2 (ru) 2013-10-07 2018-06-21 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для лечения синдрома дефицита внимания и гиперактивности, тревожности и бессонницы с применением трансдермальных композиций на основе дексмедетомидина
US11752182B2 (en) 2014-03-10 2023-09-12 Turtle Bear Holdings, Llc Integrative fungal solutions for protecting bees
ES2761776T3 (es) * 2014-12-22 2020-05-21 Suda Pharmaceuticals Ltd Prevención y tratamiento de la enfermedad metastásica en pacientes con cáncer trombocitótico
CN108776180B (zh) * 2018-03-20 2020-12-04 广西壮族自治区食品药品检验所 一种同时测定曲咪新乳膏中多种透皮吸收促进剂的检测方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2862966A (en) * 1958-12-02 archo
US3731683A (en) * 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
USRE31617E (en) * 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
JPS49132019A (de) * 1973-02-26 1974-12-18
DE2400887A1 (de) * 1974-01-09 1975-08-28 Bayer Ag Verfahren zur herstellung von nitroderivaten aromatischer verbindungen
JPS5752352B2 (de) * 1974-02-28 1982-11-06
US3983120A (en) * 1974-11-06 1976-09-28 Bristol-Myers Company Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
US3983119A (en) * 1974-11-06 1976-09-28 Bristol-Myers Company Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones
US3988340A (en) * 1975-01-23 1976-10-26 Bristol-Myers Company 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
JPS5251379A (en) * 1975-10-24 1977-04-25 Sumitomo Chem Co Ltd Preparation 3,4-dihydro-2(1h)-quinazoline derivates
JPS5291885A (en) * 1976-01-23 1977-08-02 Sumitomo Chem Co Ltd 3,4-dihydro-2(1h)-quinazolinone derivatives
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
US4146718A (en) * 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
US4208521A (en) * 1978-07-31 1980-06-17 Bristol-Myers Company Process for the preparation of imidazo[2,1-b]quinazolinones
ZW16481A1 (en) * 1980-08-15 1982-03-10 Hoffmann La Roche Novel imidazoquinazoline derivatives
US4444777A (en) * 1981-07-30 1984-04-24 Bristol-Myers Company Pharmaceutical compositions of anagrelide and sulfinpyrazone
US4357330A (en) * 1981-07-30 1982-11-02 Bristol-Myers Company Pharmaceutical compositions
US4455311A (en) * 1981-08-28 1984-06-19 Hoffmann-La Roche Inc. Imidazoquinazoline derivatives which inhibit the aggregation of blood platelets, inhibit gastric secretion or have activity on the circulatory system
JPS6028979A (ja) * 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン類化合物
US4837239A (en) * 1985-08-23 1989-06-06 Syntex (U.S.A.) Inc. Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins
EP0244525B1 (de) * 1986-05-08 1990-07-25 International Business Machines Corporation Plattenspeicher mit Luftfiltrierungsanlage
US4906169A (en) 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
JPH088287Y2 (ja) 1988-02-22 1996-03-06 日産自動車株式会社 Ｄｏｈｃ４バルブ型内燃機関のシリンダヘッド
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4847276A (en) * 1988-09-06 1989-07-11 Merrell Dow Pharmaceuticals Inc. Treatment of thromobocytosis with 5-(4-chlorophenyl)-2,4-diemthyl-3H-1,2,4-triazole-3-thione
MX21452A (es) * 1989-07-07 1994-01-31 Ciba Geigy Ag Preparaciones farmaceuticas que se administran en forma topica.
US5043327A (en) * 1989-07-18 1991-08-27 Janssen Pharmaceutica N.V. Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives, compositions and use
US5391737A (en) * 1991-05-22 1995-02-21 Egis Gyogyszergyar Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one
US5232702A (en) 1991-07-22 1993-08-03 Dow Corning Corporation Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
US5230897A (en) * 1991-10-31 1993-07-27 G. D. Searle & Co. Transdermal pentamidine
US5306709A (en) * 1991-11-15 1994-04-26 The University Of Pennsylvania Suppression of megakaryocytopoiesis by macrophage inflammatory proteins
AU3071492A (en) * 1991-11-15 1993-06-15 University Of Pennsylvania Suppression of megakaryocytopoiesis by neutrophil activating peptide-2
US6024975A (en) * 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
PL174770B1 (pl) * 1992-12-07 1998-09-30 Lohmann Therapie Syst Lts Przezskórny układ terapeutyczny do terapii przeciwzakrzepowej i/lub zapobiegania chorobom nowotworowym oraz sposób wytwarzania przezskórnego układu terapeutycznego do terapii przeciwzakrzepowej i/lub zapobiegania chorobom nowotworowym
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
CA2171073A1 (en) * 1995-12-04 1997-06-05 Philip C. Lang Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
EP0961616A4 (de) * 1996-09-13 2000-11-22 Trustees Of Board Of Nicht-hormonale verhuetungsmethode
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US5874437A (en) * 1996-11-01 1999-02-23 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
WO1999020223A2 (en) * 1997-10-20 1999-04-29 Novo Nordisk A/S Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6156753A (en) * 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6548529B1 (en) * 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6493180B1 (en) * 1999-08-19 2002-12-10 Samsung Electronics Co., Ltd. Hard disk drive cover that contains a helmholtz resonator which attenuates acoustic energy
JP2003509478A (ja) * 1999-09-21 2003-03-11 エモリー・ユニバーシティ 血小板関連障害を処置する方法および組成物
US6194420B1 (en) * 1999-11-30 2001-02-27 Roberts Laboratories Inc. 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof
US20020004065A1 (en) * 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
US6987640B2 (en) * 2000-07-26 2006-01-17 Seagate Technology Llc Two-part flow conditioning apparatus for a disc drive
US6388073B1 (en) * 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
TNSN03127A1 (fr) * 2001-05-31 2005-12-23 Pharmacia Corp Composition d'inhibiteur de cyclo-oxygenase-2-selectif, apte a la penetration dermique
US20030181461A1 (en) * 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US20030235609A1 (en) * 2002-01-25 2003-12-25 Lautt Wilfred Wayne Use of cholinesterase antagonists to treat insulin resistance
US20030114673A1 (en) * 2002-05-29 2003-06-19 Lang Philip C. 2-amino-5,6-dihalo-3,4-dihydroquinazolines with blood platelet reducing properties
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
EP1776108A1 (de) * 2004-06-23 2007-04-25 Myogen, Inc. Enoximon-formulierungen und ihre verwendung bei der behandlung von pde-iii-vermittelten erkrankungen

Also Published As

Publication number Publication date
OA13018A (en) 2006-11-10
CO5640120A2 (es) 2006-05-31
CN1738623A (zh) 2006-02-22
EA010871B1 (ru) 2008-12-30
AU2004206783A1 (en) 2004-08-05
PT1589973E (pt) 2010-07-09
IL169153A (en) 2011-01-31
HK1075844A1 (en) 2005-12-30
EP1589973B1 (de) 2010-04-07
EP1589973A1 (de) 2005-11-02
JP4624978B2 (ja) 2011-02-02
EP1589973B2 (de) 2012-12-26
EA200501166A1 (ru) 2006-02-24
ZA200506056B (en) 2006-05-31
NO20053874L (no) 2005-10-19
CA2513708C (en) 2011-01-04
DE602004026405D1 (de) 2010-05-20
NO20053874D0 (no) 2005-08-18
BRPI0406634A (pt) 2005-12-06
EA200801731A1 (ru) 2009-10-30
CY1110162T1 (el) 2015-01-14
ES2344062T3 (es) 2010-08-17
CA2513708A1 (en) 2004-08-05
MXPA05007287A (es) 2005-12-12
SI1589973T1 (sl) 2010-08-31
KR20050111317A (ko) 2005-11-24
SI1589973T2 (sl) 2013-05-31
PL377933A1 (pl) 2006-02-20
DK1589973T4 (da) 2013-04-08
SG153661A1 (en) 2009-07-29
IL169153A0 (en) 2007-07-04
ES2344062T5 (es) 2013-04-26
US20040209907A1 (en) 2004-10-21
WO2004064841A1 (en) 2004-08-05
HRP20050633A2 (en) 2006-06-30
NO330805B1 (no) 2011-07-18
DK1589973T3 (da) 2010-07-19
RS20050524A (en) 2007-11-15
JP2006516563A (ja) 2006-07-06
AP2005003362A0 (en) 2005-09-30
AU2004206783B2 (en) 2009-03-26
AP2103A (en) 2010-02-08

Similar Documents

Publication Publication Date Title
DE60231601D1 (de) Einrichtung und verfahren zur behandlung
DE60335921D1 (de) Thrombusdetektor, vorrichtung zur behandlung von thromben und verfahren dafür
DE60319294D1 (de) Vorrichtung und Verfahren zur Substratbehandlung
DE60227095D1 (de) Zusammensetzungen und verfahren zur behandlung von abgebundenem gips
DE602004021790D1 (de) Verfahren zur behandlung von parkinson-krankheit
ATE489955T1 (de) Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
DE60335293D1 (de) Pyrrolopyridazin-verbindungen und verwendungsverfahren dafür zur behandlung von proliferativen erkrankungen
DE602004006790D1 (de) Verfahren und Gerät zur Klassifikation von Defekten
DE602004010705D1 (de) Vorrichtung und Verfahren zur Behandlung von Mist enthaltendem Abwasser
DE50304943D1 (de) Verfahren und vorrichtung zur herstellung von borsten
DE602004022776D1 (de) Vorrichtung mit verlängerter freisetzung und verfahren zur okularen verabreichung von adrenergen wirkstoffen
ATE463246T1 (de) Formulierung und verfahren zur behandlung von thrombocythämie
DE602004016422D1 (de) Verfahren und Vorrichtung zur Prüfung von Halbleiterelementen
DE60304078D1 (de) Verfahren und Vorrichtung zur Durchfürung von Interfrequenz-Messungen
DE602004016712D1 (de) Vorrichtung und Verfahren zur Bestimmung von Blutkomponenten
ATE505811T1 (de) Verfahren zur nassbehandlung von scheibenförmigen gegenständen
DE60303855D1 (de) Verfahren und Vorrichtung zur Akquisition von zellulären Netzen
DE50214806D1 (de) Verfahren und vorrichtung zur abgasnachbehandlung
DE60327856D1 (de) Zusammensetzungen und verfahren zur hautbräunung
ATE374799T1 (de) Verfahren zur behandlung von pigmenten in partikulärer form
DE50213931D1 (de) Verfahren und vorrichtung zur behandlung von fehlerverdacht
DE60313561D1 (de) Verfahren und Vorrichtung zur Akquisition von zellulären Netzen
DE50304803D1 (de) Verfahren zur instandsetzung und fertigung von geometrisch komplexen bauteilen
DE602004010548D1 (de) Verfahren zur behandlung von tierhäuten
DE60334782D1 (de) Verfahren und vorrichtung zur herstellung von halbcluster

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1589973

Country of ref document: EP

EEIH Change in the person of patent owner